Clinical Trial Detail

NCT ID NCT03212274
Title Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

cholangiocarcinoma

malignant glioma

Advanced Solid Tumor

Therapies

Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST